|
|
SPOT ON
|
|
The 800 million dollar myth … What does drug development actually cost?
|
|
|
NEW ON THE MARKET
|
|
Oral immunosuppressant fingolimod (GILENYA) for multiple sclerosis
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Bevacizumab: alternative to ranibizumab for macular degeneration
|
|
|
a-t READER'S QUESTIONS AND COMMENTS
|
|
Costs of coagulation self-testing
|
|
|
IN BRIEF
|
|
´Gastroenterology´ retracts study on pancreatitis with exenatide (BYETTA) and sitagliptin (JANUVIA, XELEVIA)
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Agranulocytosis and anaphylaxis due to metamizol (NOVALGIN, generics)
|
|
|
SIDE EFFECTS
|
|
Update: progressive leukencephalopathy with natalizumab (TYSABRI)
New data on thromboembolism due to oral contraceptives containing drospirenone
|
|
|
e a-t IN THE INTERNET
|
|
Great Britain: no routine pneumococcal vaccination of elderly
Confirmed: Swine flu vaccine (PANDEMRIX) and narcolepsy
|
|